US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.

At JP Morgan last month, pharmaphorum editor-in-chief Jonah Comstock caught up with Paul Hastings, the CEO of Nkarta, to talk ...

During a recent Q&A at The NAMM Show, Peter Frampton discusses his new tour and his health status as he battles the muscle disorder IBM.

This latest tour joins Frampton's recent run of shows following a diagnosis of inclusion body myositis (IBM), a degenerative disease of the muscles, in 2019. After a brief flirting with a farewell ...

Pepper’s Lonely Hearts Club Band” film retired from playing live music in 2019 after sharing he’d been diagnosed with Inclusion-Body Myositis (IBM). Although his fingers aren’t quite as ...